[go: up one dir, main page]

CY1115254T1 - PHARMACEUTICAL SOLUTIONS, PROCEDURES FOR PREPARATION AND THERAPEUTIC USES - Google Patents

PHARMACEUTICAL SOLUTIONS, PROCEDURES FOR PREPARATION AND THERAPEUTIC USES

Info

Publication number
CY1115254T1
CY1115254T1 CY20141100513T CY141100513T CY1115254T1 CY 1115254 T1 CY1115254 T1 CY 1115254T1 CY 20141100513 T CY20141100513 T CY 20141100513T CY 141100513 T CY141100513 T CY 141100513T CY 1115254 T1 CY1115254 T1 CY 1115254T1
Authority
CY
Cyprus
Prior art keywords
preparation
procedures
therapeutic uses
pharmaceutical solutions
pharmaceutical
Prior art date
Application number
CY20141100513T
Other languages
Greek (el)
Inventor
Eric Schenkel
Claire Poulain
Bertrand Dodelet
Domenico Fanara
Original Assignee
Ucb Pharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115254(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma, S.A. filed Critical Ucb Pharma, S.A.
Publication of CY1115254T1 publication Critical patent/CY1115254T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ένα σταθερό φαρμακευτικό διάλυμα, σε μία διαδικασία για την παρασκευή του και στις θεραπευτικές χρήσεις του.The present invention relates to a stable pharmaceutical solution, to a process for its preparation and therapeutic uses.

CY20141100513T 2008-03-03 2014-07-08 PHARMACEUTICAL SOLUTIONS, PROCEDURES FOR PREPARATION AND THERAPEUTIC USES CY1115254T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003915 2008-03-03
EP09716304.2A EP2273975B8 (en) 2008-03-03 2009-03-02 Pharmaceutical solutions, process of preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
CY1115254T1 true CY1115254T1 (en) 2017-01-04

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100513T CY1115254T1 (en) 2008-03-03 2014-07-08 PHARMACEUTICAL SOLUTIONS, PROCEDURES FOR PREPARATION AND THERAPEUTIC USES

Country Status (21)

Country Link
US (1) US20110021786A1 (en)
EP (1) EP2273975B8 (en)
JP (6) JP2011513360A (en)
KR (1) KR101353425B1 (en)
CN (1) CN101945647B (en)
AU (1) AU2009221177B2 (en)
BR (1) BRPI0908421C1 (en)
CA (1) CA2715685C (en)
CY (1) CY1115254T1 (en)
DK (1) DK2273975T3 (en)
EA (1) EA018736B1 (en)
ES (1) ES2474945T3 (en)
HK (1) HK1148202A1 (en)
HR (1) HRP20140634T1 (en)
IL (1) IL207558A (en)
MX (1) MX2010009222A (en)
PL (1) PL2273975T3 (en)
PT (1) PT2273975E (en)
RS (1) RS53418B (en)
SI (1) SI2273975T1 (en)
WO (1) WO2009109547A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009222A (en) * 2008-03-03 2010-09-28 Ucb Pharma Sa Pharmaceutical solutions, process of preparation and therapeutic uses.
CA2740610C (en) * 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
ES2588504T3 (en) 2008-10-22 2016-11-03 Array Biopharma, Inc. Pyrazolo [1,5-a] pyrimidine compounds substituted as intermediates in the synthesis of TRK kinase inhibitors
DK2358361T3 (en) * 2008-11-18 2016-12-12 Ucb Biopharma Sprl DEPOT formulation comprising a 2-oxo-1-pyrrolidine.
PL2790695T3 (en) 2011-12-16 2016-07-29 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A Pharmaceutical composition comprising (s)-2-(2-oxopyrrolidin-1-yl)butanamid
CN102525900A (en) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 Levetiracetam injection and preparation method thereof
AU2013249034B2 (en) * 2012-04-19 2016-04-28 C. R. Bard, Inc. Infusates with enhanced pH stability under ethylene oxide sterilization
JP6440625B2 (en) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and compositions for treating schizophrenia
CN105142623A (en) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
CN103550143B (en) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 A kind of preparation method of levetiracetam injection
EA034167B8 (en) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Extended release pharmaceutical compositions of levetiracetam
MX2018008021A (en) 2015-12-30 2018-11-09 Adamas Pharmaceuticals Inc Methods and compositions for the treatment of seizure-related disorders.
DK3439662T3 (en) 2016-04-04 2024-09-02 Loxo Oncology Inc LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUORPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLE[1,5-A]PYRIMIDIN-3-YL)-3 -HYDROXYPYRROLIDINE-1-CARBOXAMIDE
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3800189T3 (en) 2016-05-18 2023-07-31 Loxo Oncology Inc PREPARATION OF (S)-N-(5-((R)-2-(2,5-DIFLUORPHENYL)PYRROLIDIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDIN- 1-CARBOXAMIDE
CN106491523A (en) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 A kind of Bu Waxitan oral administration solutions and preparation method thereof
US20210161808A1 (en) * 2018-07-24 2021-06-03 Zenvision Pharma Llp Nasal Drug Delivery System of Brivaracetam or Salt Thereof
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
EP3951452A4 (en) 2019-03-28 2022-12-28 Toyobo Co., Ltd. ANTI-REFLECTIVE CIRCULAR POLARIZER AND IMAGE DISPLAY DEVICE THEREOF
CN113908120A (en) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 Brivaracetam drug solution and preparation method thereof
CN114213306A (en) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 Preparation method of brivaracetam acid impurity
EP4505994A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution formulation comprising brivaracetam
EP4505995A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution composition comprising brivaracetam
WO2025038056A1 (en) * 2023-08-11 2025-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi An oral solution comprising brivaracetam
EP4505996A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. An oral solution comprising brivaracetam
CN118986873A (en) * 2024-08-19 2024-11-22 海南卫康制药(潜山)有限公司 Brivarenical tablets preparation of the tam solution method and brivaracetam solution

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1758855B1 (en) * 2004-06-11 2007-11-21 UCB Pharma, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
MX2010009222A (en) * 2008-03-03 2010-09-28 Ucb Pharma Sa Pharmaceutical solutions, process of preparation and therapeutic uses.
KR101286540B1 (en) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 Liquid crystal display

Also Published As

Publication number Publication date
JP2015145382A (en) 2015-08-13
EA018736B1 (en) 2013-10-30
DK2273975T3 (en) 2014-06-30
JP2011513360A (en) 2011-04-28
SI2273975T1 (en) 2014-09-30
US20110021786A1 (en) 2011-01-27
PT2273975E (en) 2014-07-17
EP2273975B1 (en) 2014-04-09
KR101353425B1 (en) 2014-02-18
EA201001402A1 (en) 2011-06-30
RS53418B (en) 2014-12-31
ES2474945T3 (en) 2014-07-10
CA2715685A1 (en) 2009-09-11
BRPI0908421A2 (en) 2015-08-04
EP2273975B8 (en) 2014-12-17
AU2009221177B2 (en) 2013-05-30
HRP20140634T1 (en) 2014-11-21
KR20100126466A (en) 2010-12-01
CN101945647B (en) 2013-01-09
JP2017114890A (en) 2017-06-29
IL207558A0 (en) 2010-12-30
PL2273975T3 (en) 2014-09-30
JP2019089837A (en) 2019-06-13
HK1148202A1 (en) 2011-09-02
CN101945647A (en) 2011-01-12
CA2715685C (en) 2015-04-28
BRPI0908421C1 (en) 2021-05-25
WO2009109547A1 (en) 2009-09-11
EP2273975A1 (en) 2011-01-19
BRPI0908421B1 (en) 2020-08-04
JP2022169734A (en) 2022-11-09
JP2020128384A (en) 2020-08-27
IL207558A (en) 2015-02-26
MX2010009222A (en) 2010-09-28
AU2009221177A1 (en) 2009-09-11
BRPI0908421B8 (en) 2020-08-18

Similar Documents

Publication Publication Date Title
CY1115254T1 (en) PHARMACEUTICAL SOLUTIONS, PROCEDURES FOR PREPARATION AND THERAPEUTIC USES
CY1121742T1 (en) S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF
CY1116264T1 (en) ANTIBODIES AGAINST HUMAN VASCULAR 2
CY1119058T1 (en) IMIDAZOPYRROLIDINONE COMPOUNDS
EA201170753A1 (en) NALMEPHENA HYDROCHLORIDE DIHYDRATE
CY1113024T1 (en) CYCLOXEXANE SPIRACYCLIC PRODUCTS FOR TREATMENT OF SUBSTANCE ADDICTION
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
EA201270619A1 (en) USE OF BETANEHOL FOR THE TREATMENT OF XEROSTOMY
CY1119798T1 (en) FORM IV IV Hydrochloride Ibabradine
CY1115932T1 (en) ANTIBODY PACKAGING
CY1115030T1 (en) SPECIAL ANTI-VEGF / ANTI-ANG-2 ANTIBODIES
CY1124331T1 (en) INCREASED BIOAVAILABILITY OF ACTIVE SUBSTANCE IN NALTREXONE THERAPY
CY1120758T1 (en) STABLE ORAL SOLUTIONS FOR COMBINED EFS
CY1120094T1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DESPR036 EXPANDH-4 (1-39) -LYS6-NH2 FOR USE IN THE TREATMENT OF A NEUROCOLOGICAL PATIENT
LT2451482T (en) COMBINED THERAPY FOR DIABETES TREATMENT
CY1122711T1 (en) METHOD FOR ACTIVATION AND COUPLING OF BIOMOLECULES
CY1117163T1 (en) IMIDAZYPYRIDAZINS AS ACTIVE MODELS
EA201200484A1 (en) PHARMACEUTICAL COMPOSITION WITH EXISTING SUBSTANCES - METHORMIN AND SYTAGLIPTIN OR VILDAGLIPTIN
CY1115437T1 (en) Hydroxymethylcyclohexylamines
CY1115975T1 (en) TAPENTADOLI FOR ARTHRITIS PAIN TREATMENT
MX2010006206A (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases.
CR20110552A (en) TREATMENT OF INSULIN RESISTANT DISORDERS
CY1113551T1 (en) Substituted nicotinamide compounds and their use in medicinal products
EA200970816A1 (en) NEW MEDICINE FORM
EA200801678A1 (en) APPLICATION OF TRIAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICINE PRODUCT WITH A HEALING OR ANGIOGEN EFFECT